(19)
(11)EP 3 564 224 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
27.11.2019 Bulletin 2019/48

(43)Date of publication A2:
06.11.2019 Bulletin 2019/45

(21)Application number: 19174923.3

(22)Date of filing:  17.07.2015
(51)Int. Cl.: 
C07D 295/096  (2006.01)
A61P 25/00  (2006.01)
A61K 31/495  (2006.01)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 18.07.2014 IT MI20141319
24.09.2014 IT MI20141657

(62)Application number of the earlier application in accordance with Art. 76 EPC:
15177222.5 / 2975032

(71)Applicant: Dipharma Francis S.r.l.
20021 Baranzate (MI) (IT)

(72)Inventors:
  • GIAFFREDA, Stefano Luca
    20021 Baranzate (MI) (IT)
  • CURZI, Marco
    20021 Baranzate (MI) (IT)
  • DICHIARANTE, Elena
    20021 Baranzate (MI) (IT)
  • ALLEGRINI, Pietro
    20021 Baranzate (MI) (IT)
  • GRAZIOSI, Renzo
    20021 Baranzate (MI) (IT)
  • VLADISKOVIC, Chiara
    20021 Baranzate (MI) (IT)

(74)Representative: Bianchetti Bracco Minoja S.r.l. 
Via Plinio, 63
20129 Milano
20129 Milano (IT)

  


(54)CRYSTALLINE FORM OF VORTIOXETINE HYDROBROMIDE AS ANTIDEPRESSANT DRUG


(57) The present invention relates to novel crystalline forms of vortioxetine hydrobromide, in particular three crystalline forms, a process for their preparation, a pharmaceutical composition containing said novel crystalline forms, and a process for the purification of vortioxetine or a salt thereof, comprising the formation of one or more of the novel crystalline forms of vortioxetine hydrobromide described herein.